SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Microcap & Penny Stocks : TLT.v
TLT.V 0.3100.0%Dec 13 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Liberator11/1/2019 9:30:38 AM
  Read Replies (1) of 1471
 
I still have less than a full position in this...thank goodness.
Is Kipton's departure a positive or negative?

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today the departure of its Chief Executive Officer - Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth." style="margin: 0px 0px 1em; font-family: Georgia, "Times New Roman", serif; font-size: 18px; background-color: rgb(255, 255, 255);">TORONTO, ON / ACCESSWIRE / October 31, 2019 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today the departure of its Chief Executive Officer - Device Division, Kipton Lade from the Company. Effective immediately, Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, has agreed to become the sole CEO of the Company and will work with the Board to begin a search to identify a new leader to guide the Device Division in its next phase of growth.

"We thank Kipton for his contributions to the Company over the last 8 months and we wish him well," said Theralase Technologies Chairman of the Board of Directors, Guy Anderson. "We are also excited with the prospects of the TLD-1433 Anti-Cancer Technology ("ACT") platform as it has the potential to be a viable treatment solution for patients who present with Carcinoma In-Situ ("CIS") Non-Muscle Invasive Bladder Cancer ("NMIBC") and who are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive."

The Company has commenced a Phase II NMIBC clinical study to enroll and treat patients who present with CIS and who are considered BCG-Unresponsive or are intolerant to BCG Therapy ("Study II"). The Company has three sites open for patient enrollment and treatment; specifically, University Health Network ("UHN"), McGill University Health Centre ("MUHC") and London Health Sciences Centre ("LHSC"). All sites are actively recruiting and screening new patients for enrollment in Study II. In addition, the Company has approximately six clinical study sites located in Canada and the US that are at various stages of the on-boarding process. The Company is specifically targeting strategic clinical sites throughout Canada and the US (subject to FDA Investigational New Drug ("IND") approval) that serve large populations or have the demographics to support patient enrollment and treatment. The Company anticipates that patient enrollment and treatment will escalate rapidly as it launches additional clinical study sites.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="About Theralase® Technologies Inc." style="margin: 0px 0px 1em; font-family: Georgia, "Times New Roman", serif; font-size: 18px; background-color: rgb(255, 255, 255);">About Theralase® Technologies Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext